Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052).

Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052).

BACKGROUND: This was a prospective phase II study of cisplatin and bortezomib (CB) in the first line treatment of malignant pleural mesothelioma (MPM) with validation of progression free survival rate at 18 weeks (PFSR-18)(1) as primary end-point. METHODS: Chemotherapy-naïve patients with histologi...

Full description

Bibliographic Details
Main Authors: O'Brien, M, Gaafar, R, Popat, S, Grossi, F, Price, A, Talbot, D, Cufer, T, Ottensmeier, C, Danson, S, Pallis, A, Hasan, B, Van Meerbeeck, J, Baas, P
Format: Journal article
Language:English
Published: 2013

Similar Items

Similar Items